Correlation Between Apellis Pharmaceuticals and Regenxbio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Regenxbio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Regenxbio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and Regenxbio, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Regenxbio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Regenxbio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Regenxbio.

Diversification Opportunities for Apellis Pharmaceuticals and Regenxbio

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Apellis and Regenxbio is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Regenxbio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Regenxbio and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Regenxbio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Regenxbio has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Regenxbio go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Regenxbio

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to under-perform the Regenxbio. But the stock apears to be less risky and, when comparing its historical volatility, Apellis Pharmaceuticals is 1.32 times less risky than Regenxbio. The stock trades about -0.04 of its potential returns per unit of risk. The Regenxbio is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  1,134  in Regenxbio on August 31, 2024 and sell it today you would lose (133.00) from holding Regenxbio or give up 11.73% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Apellis Pharmaceuticals  vs.  Regenxbio

 Performance 
       Timeline  
Apellis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Regenxbio 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Regenxbio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Regenxbio is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Apellis Pharmaceuticals and Regenxbio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Apellis Pharmaceuticals and Regenxbio

The main advantage of trading using opposite Apellis Pharmaceuticals and Regenxbio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Regenxbio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regenxbio will offset losses from the drop in Regenxbio's long position.
The idea behind Apellis Pharmaceuticals and Regenxbio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories